Truvian Sciences Raises More Than $105 Million in Oversubscribed Series C Financing Funding Will Accelerate FDA Submission and Commercialization of Automated Benchtop Blood Testing System TYH Ventures, Glen Tullman of 7WireVentures, and Wittington Ventures Led the Round, Joined by General Catalyst, GreatPoint Ventures, DNS Capital, and Wasson Enterprise Prominent Industry Leaders Join Executive Team and Board of Directors News provided by Share this article Share this article SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Truvian Sciences ("Truvian") today announced the close of more than $105 million in an oversubscribed Series C financing round led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures. The funds will advance development of Truvian's automated benchtop blood testing system, paving the way to submit the device for U.S. Food and Drug Administration (FDA) clearance, and enabling the company to scale its team in preparation for broad commercialization. Inclusive of the Series C, Truvian has raised more than $150 million in funding to date.